In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

Earnings per share (EPS) missed analyst estimates significantly ... compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on TEVA: Teva Pharmaceutical Industries NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

Teva Pharmaceutical Industries' Q4 2024 results ... A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates seems achievable should Teva outperform lowered EPS and sales estimates.

Teva Pharmaceutical (NYSE ... The stock closed 1.67% lower at $17.06 on Tuesday. Despite topping Q4 EPS and revenue expectations, shares of TEVA declined 13% on January 29 as the drugmaker set ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA ... For all of 2024, Teva recorded diluted EPS of $2.49 ex-items - above estimates of $2.47 - compared with $2.56 in 2023.

Shares of Teva Pharmaceutical Industries (NYSE ... Its earnings per share (EPS) for Q4 was $0.71, down significantly from Q4 2023's $1.00, but slightly exceeding an expected $0.70.

Check This Out: Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lag Outlook: Teva Pharmaceutical expects full-year 2025 revenue to be in the range of $16.8 billion to $17.4 billion ...